Erratum: Tubastatin A/ACY-1215 Improves Cognition in Alzheimer's Disease Transgenic Mice (Journal of Alzheimer's Disease (2014) 41:4 (1193-1205) DOI: 10.3233/JAD-140066);Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice

Journal of Alzheimer's Disease

Volumn 41, Issue 4, 2014, Pages 1193-1205

  Zhang, Ling ^a   Liu, Cui ^a   Wu, Jie ^a   Tao, Jing Jing ^a   Sui, Xiao Long ^a   Yao, Zhi Gang ^a   Xu, Yan Feng ^a   Huang, Lan ^a   Zhu, Hua ^a   Sheng, Shu Li ^a   Qin, Chuan ^a  

^a INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

Author keywords

Alzheimer's disease; amyloid; autophagy; histone deacetylase (HDAC); tau

Indexed keywords

HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; RICOLINOSTAT; TUBASTATIN A; UNCLASSIFIED DRUG; 2-(DIPHENYLAMINO)-N-(7-(HYDROXYAMINO)-7-OXOHEPTYL)PYRIMIDINE-5-CARBOXAMIDE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; HDAC6 PROTEIN, MOUSE; HISTONE DEACETYLASE; HYDROXAMIC ACID; INDOLE DERIVATIVE; PEPTIDE FRAGMENT; PRESENILIN 1; PSEN1 PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; TUBULIN;

ACETYLATION; ALZHEIMER DISEASE; ARTICLE; AUTOPHAGY; COGNITIVE DEFECT; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; IMMUNOBLOTTING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRANSGENIC MOUSE; ANIMAL; BRAIN; C57BL MOUSE; COGNITION DISORDERS; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MAZE TEST; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; ULTRASTRUCTURE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INDOLES; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PRESENILIN-1; PYRIMIDINES; TUBULIN;

EID: 84921951885     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-249014     Document Type: Erratum

References (53)

1. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M (2012) Epigenetic protein families: A new frontier for drug discovery. Nat Rev Drug Discov 11, 384-400.
2. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222.
3. Graff J, Tsai LH (2013) The potential of HDAC inhibitors as cognitive enhancers. Annu Rev Pharmacol Toxicol 53, 311-330.
4. Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, Rumbaugh G (2010) Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 35, 870-880.
5. Kazantsev AG, Thompson LM (2008) Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 7, 854-868.
6. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417, 455-458.
7. Zhang L, Sheng S, Qin C (2013) The role of HDAC6 in Alzheimer's disease. J Alzheimers Dis 33, 283-295.
8. Ding H, Dolan PJ, Johnson GV (2008) Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem 106, 2119-2130.
9. Perez M, Santa-Maria I, Gomez de Barreda E, Zhu X, Cuadros R, Cabrero JR, Sanchez-Madrid F, Dawson HN, Vitek MP, Perry G, Smith MA, Avila J (2009) Tau-an inhibitor of deacetylase HDAC6 function. J Neurochem 109, 1756-1766.
10. Odagiri S, Tanji K, Mori F, Miki Y, Kakita A, Takahashi H, Wakabayashi K (2013) Brain expression level and activity of HDAC6 protein in neurodegenerative dementia. Biochem Biophys Res Commun 430, 394-399.
11. Govindarajan N, Rao P, Burkhardt S, Sananbenesi F, Schluter OM, Bradke F, Lu J, FischerA(2013) ReducingHDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. EMBO Mol Med 5, 52-63.
12. Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, Kozikowski AP (2010) Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 132, 10842-10846.
13. Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, Cirstea D, Rodig S, Eda H, Scullen T, Canavese M, Bradner J, Anderson KC, Jones SS, Raje N (2012) Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 119, 2579-2589.
14. Yao ZG, Zhang L, Liang L, Liu Y, Yang YJ, Huang L, Zhu H, Ma CM, Qin C (2013) The effect of PN-1, a traditional Chinese prescription, on the learning and memory in a transgenic mouse model of Alzheimer's disease. Evid Based Complement Alternat Med 2013, 518421.
15. d'Ydewalle C, Krishnan J, Chiheb DM,Van Damme P, Irobi J, KozikowskiAP,Vanden Berghe P, TimmermanV, Robberecht W,Van Den Bosch L (2011)HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med 17, 968-974.
16. Zhang L, Ma Q, YangW, Qi X, Yao Z, Liu Y, Liang L,Wang X, Ma C, Huang L, Xu Y, Zhu H, Deng W, Gao Y, Ruan L, Xiao Z, Qin C (2013) Recombinant DNA vaccine against neurite outgrowth inhibitors attenuates behavioral deficits and decreases Abeta in an Alzheimer's disease mouse model. Neuropharmacology 70, 200-210.
17. Nemirovsky A, Shapiro J, Baron R, Kompaniets A, Monsonego A (2012) Active Abeta vaccination fails to enhance amyloid clearance in a mouse model of Alzheimer's disease with Abeta42-driven pathology. J Neuroimmunol 247, 95-99.
18. Dompierre JP, Godin JD, Charrin BC, Cordelieres FP, King SJ, Humbert S, Saudou F (2007) Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci 27, 3571-3583.
19. O'Brien RJ, Wong PC (2011) Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci 34, 185-204.
20. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19, 5720-5728.
21. Jaeger PA, Wyss-Coray T (2010) Beclin 1 complex in autophagy and Alzheimer disease. Arch Neurol 67, 1181-1184.
22. Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, Massey AC, Sovak G, Uchiyama Y, Westaway D, Cuervo AM, Nixon RA (2010) Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141, 1146-1158.
23. Nixon RA (2013) The role of autophagy in neurodegenerative disease. Nat Med 19, 983-997.
24. Nazio F, Strappazzon F, Antonioli M, Bielli P, Cianfanelli V, Bordi M, Gretzmeier C, Dengjel J, Piacentini M, Fimia GM, Cecconi F (2013) mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. Nat Cell Biol 15, 406-416.
25. Kim J, Kundu M, Viollet B, Guan KL (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13, 132-141.
26. Ravikumar B,Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, EastonDF, Duden R, O'Kane CJ, RubinszteinDC (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36, 585-595.
27. Guthrie CR, KraemerBC(2011) Proteasome inhibition drives HDAC6-dependent recruitment of tau to aggresomes. J Mol Neurosci 45, 32-41.
28. Cook C, Gendron TF, Scheffel K, Carlomagno Y, Dunmore J, DeTure M, Petrucelli L (2012) Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation. Hum Mol Genet 21, 2936-2945.
29. XiongY, Zhao K,Wu J,XuZ, Jin S, ZhangYQ(2013)HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila. Proc Natl Acad Sci U S A 110, 4604-4609.
30. Liu F, Liang Z, Shi J, Yin D, El-Akkad E, Grundke-Iqbal I, Iqbal K, Gong CX (2006) PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinasespecific manners. FEBS Lett 580, 6269-6274.
31. Hur EM, Zhou FQ (2010) GSK3 signalling in neural development. Nat Rev Neurosci 11, 539-551.
32. Dallavalle S, Pisano C, Zunino F (2012) Development and therapeutic impact of HDAC6-selective inhibitors. Biochem Pharmacol 84, 756-765.
33. Haggarty SJ,KoellerKM,Wong JC, GrozingerCM,Schreiber SL (2003) Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 100, 4389-4394.
34. Estiu G, Greenberg E, Harrison CB, Kwiatkowski NP, Mazitschek R, Bradner JE, Wiest O (2008) Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J Med Chem 51, 2898-2906.
35. Kim C, Choi H, Jung ES, Lee W, Oh S, Jeon NL, Mook-Jung I (2012) HDAC6 inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in hippocampal neurons. PLoS One 7, e42983.
36. Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D, Osada H, Komatsu Y, Nishino N, Khochbin S, Horinouchi S, Yoshida M (2002) In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 21, 6820-6831.
37. Bulinski JC (2007) Microtubule modification: Acetylation speeds anterograde traffic flow. Curr Biol 17, R18-R20.
38. Reed NA, Cai D, Blasius TL, Jih GT, Meyhofer E, Gaertig J, VerheyKJ (2006) Microtubule acetylation promotes kinesin-1 binding and transport. Curr Biol 16, 2166-2172.
39. Chen S, Owens GC, Makarenkova H, Edelman DB (2010) HDAC6 regulates mitochondrial transport in hippocampal neurons. PLoS One 5, e10848.
40. Asthana J, Kapoor S, Mohan R, Panda D (2013) Inhibition of HDAC6 deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells. J Biol Chem 288, 22516-22526.
41. Xie R, Nguyen S, McKeehan WL, Liu L (2010) Acetylated microtubules are required for fusion of autophagosomes with lysosomes. BMC Cell Bio 11, 89.
42. Gavilan E, Sanchez-Aguayo I, Daza P, Ruano D (2013) GSK-3beta signaling determines autophagy activation in the breast tumor cell line MCF7 and inclusion formation in the nontumor cell line MCF10A in response to proteasome inhibition. Cell Death Dis 4, e572.
43. Qi ZF, Luo YM, Liu XR,Wang RL, Zhao HP, Yan F, Song ZJ, Luo M, Ji XM (2012) AKT/GSK3beta-dependent autophagy contributes to the neuroprotection of limb remote ischemic postconditioning in the transient cerebral ischemic rat model. CNS Neurosci Ther 18, 965-973.
44. Yang Y, Wang H, Wang S, Xu M, Liu M, Liao M, Frank JA, Adhikari S, Bower KA, Shi X, Ma C, Luo J (2012) GSK3beta signaling is involved in ultraviolet B-induced activation of autophagy in epidermal cells. Int J Oncol 41, 1782-1788.
45. Parr C, Carzaniga R, Gentleman SM, Van Leuven F,Walter J, Sastre M (2012) Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-beta precursor protein. Mol Cell Biol 32, 4410-4418.
46. Cai Z,Yan LJ (2013) Rapamycin, autophagy, and Alzheimer's disease. J Biochem Pharmacol Res 1, 84-90.
47. Caccamo A, Magri A, Medina DX,Wisely EV, Lopez-Aranda MF, Silva AJ, Oddo S (2013) mTOR regulates tau phosphorylation and degradation: Implications for Alzheimer's disease and other tauopathies. Aging Cell 12, 370-380.
48. Johnson SC, Rabinovitch PS, Kaeberlein M (2013) mTOR is a key modulator of ageing and age-related disease. Nature 493, 338-345.
49. Nixon RA,Yang DS (2011) Autophagy failure in Alzheimer's disease-locating the primary defect. Neurobiol Dis 43, 38-45.
50. Wolfe DM, Lee JH, Kumar A, Lee S, Orenstein SJ, Nixon RA (2013) Autophagy failure in Alzheimer's disease and the role of defective lysosomal acidification. Eur J Neurosci 37, 1949-1961.
51. Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS, Pandey UB, Kaushik S, Tresse E, Lu J, Taylor JP, CuervoAM, Yao TP (2010) HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J 29, 969-980.
52. Qing H, He G, Ly PT, Fox CJ, Staufenbiel M, Cai F, Zhang Z, Wei S, Sun X, Chen CH, Zhou W, Wang K, Song W (2008) Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 205, 2781-2789.
53. Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, Zhang M, Yang Y, Cai F, Woodgett J, Song W (2013) Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimerassociated phenotypes. J Clin Invest 123, 224-235.